Repair Bio is harnessing gene therapy's potential to clear excess cholesterol with a platform that could reshape cardiovascular treatment.
Repair Biotechnologies is developing a novel approach to cholesterol management with its Cholesterol Degrading Platform (CDP); this innovative approach moves beyond conventional cholesterol-lowering strategies, aiming instead to degrade cholesterol at the cellular level.
The Syracuse, New York-based biotech is using unique lipid nanoparticle (LNP)-messenger RNA (mRNA) therapies designed to address the root causes of conditions stemming from localized cholesterol accumulation, setting a new standard in therapeutic interventions.
Unlike traditional methods that merely reduce LDL-cholesterol levels in the bloodstream, Repair Bio’s strategy targets the intracellular free cholesterol that is toxic to cells and a contributing factor in a variety of diseases. This approach not only promises to mitigate atherosclerosis but also shows potential in treating metabolic dysfunction-associated steatohepatitis (MASH), as evidenced by promising results in preclinical mouse models.
Atherosclerosis, marked by the buildup of arterial plaque, significantly impedes blood flow and is a major contributor to cardiovascular disease (CVD) - the leading cause of death worldwide. To address this pressing health burden, scientists at Repair Bio have developed a novel LNP-mRNA therapy, and in recent experiments, atherosclerotic mouse models treated with this therapy over a six-week period demonstrated promising results. It is an innovative approach that not only holds potential for mitigating atherosclerosis but also offers a pathway to reducing the global burden of CVD, ultimately saving lives and improving health outcomes.
The viability of this approach was further underscored when Repair Bio recently received favorable pre-IND feedback from the FDA, marking a significant milestone as the company prepares for clinical trials. We sat down with Reason, the Founder and CEO of Repair Bio, to find out more about the platform, upcoming clinical trials and tackling the Goldilocks problem in delivery systems.
------------------------------
Visit Longevity.Technology - bit.ly/3PwtH8Y
Follow Longevity.Technology on:
Twitter/X - bit.ly/3AMIXuq
Facebook - bit.ly/3z8H1v5
Instagram - bit.ly/3IDvVRX
LinkedIn - bit.ly/3yIfDmf
Find out more about Repair Biotechnologies and its novel platform here -
www.repairbiotechnologies.com/
Негізгі бет ‘We're seeing profound reversal of a number of conditions’
Пікірлер: 19